Biomarkers of Brain Damage and Inflammation in Patients with Acute Cerebral Ischemia
Objectives. To study the pathogenetic and clinical significance of hypoxic brain damage and inflammatory mediators as factors in the development of cerebral stroke and to improve diagnosis using laboratory markers of brain damage and inflammation in patients with acute cerebrovascular accident (aCVA). Materials and methods. A total of 55 patients with ischemic-type stroke at age 74 (67; 80) years were investigated, along with a reference group consisting of 25 people without stroke at age 65 (62; 66.5) years. Depending on stroke outcome, groups of patients were formed – discharged and deceased. Patients’ neurological status was assessed using standard scales and a comorbidity index. Serum and cerebrospinal fluid (CSF) concentrations of S100b protein, glial fibrillary acidic protein (GFAP), and interleukin-6 (IL-6) were determined; serum neuron-specific enolase (NSE) and cortisol were estimated by immunoenzyme assay (IFA), clinical blood tests were run, and fibrinogen content was assessed on days 1, 3, and 10 of stroke. Results. Increases in blood and CSF levels of markers of brain tissue damage and systemic inflammation in response to cerebral ischemia reflected synergy of these pathological processes in patients with stroke and their association with the severity of cerebral stroke and its outcome. Conclusions. The data obtained here indicate that the postischemic release of neuron-specific proteins, along with increases in IL-6, C-reactive protein (CRP), and cortisol levels, provide additional characterization of the severity of cerebral stroke and the body’s response to damage, and also predict disease outcome..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Neuroscience and behavioral physiology - 53(2023), 4 vom: Mai, Seite 503-508 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Voznyuk, I. A. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s11055-023-01448-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052624994 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052624994 | ||
| 003 | DE-627 | ||
| 005 | 20230804064807.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230804s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11055-023-01448-y |2 doi | |
| 035 | |a (DE-627)SPR052624994 | ||
| 035 | |a (SPR)s11055-023-01448-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Voznyuk, I. A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Biomarkers of Brain Damage and Inflammation in Patients with Acute Cerebral Ischemia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer Nature Switzerland AG 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Objectives. To study the pathogenetic and clinical significance of hypoxic brain damage and inflammatory mediators as factors in the development of cerebral stroke and to improve diagnosis using laboratory markers of brain damage and inflammation in patients with acute cerebrovascular accident (aCVA). Materials and methods. A total of 55 patients with ischemic-type stroke at age 74 (67; 80) years were investigated, along with a reference group consisting of 25 people without stroke at age 65 (62; 66.5) years. Depending on stroke outcome, groups of patients were formed – discharged and deceased. Patients’ neurological status was assessed using standard scales and a comorbidity index. Serum and cerebrospinal fluid (CSF) concentrations of S100b protein, glial fibrillary acidic protein (GFAP), and interleukin-6 (IL-6) were determined; serum neuron-specific enolase (NSE) and cortisol were estimated by immunoenzyme assay (IFA), clinical blood tests were run, and fibrinogen content was assessed on days 1, 3, and 10 of stroke. Results. Increases in blood and CSF levels of markers of brain tissue damage and systemic inflammation in response to cerebral ischemia reflected synergy of these pathological processes in patients with stroke and their association with the severity of cerebral stroke and its outcome. Conclusions. The data obtained here indicate that the postischemic release of neuron-specific proteins, along with increases in IL-6, C-reactive protein (CRP), and cortisol levels, provide additional characterization of the severity of cerebral stroke and the body’s response to damage, and also predict disease outcome. | ||
| 650 | 4 | |a ischemic stroke |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a inflammation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a S100b |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a GFAP |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NSE |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a IL-6 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CRP |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a cortisol |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Pivovarova, L. P. |4 aut | |
| 700 | 1 | |a Gogoleva, E. A. |4 aut | |
| 700 | 1 | |a Osipova, I. V. |4 aut | |
| 700 | 1 | |a Ariskina, O. B. |4 aut | |
| 700 | 1 | |a Morozova, E. M. |4 aut | |
| 700 | 1 | |a Chernyavsky, I. V. |4 aut | |
| 700 | 1 | |a Markelova, E. V. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuroscience and behavioral physiology |d New York, NY : Consultants Bureau, 1967 |g 53(2023), 4 vom: Mai, Seite 503-508 |w (DE-627)SPR016109880 |w (DE-600)2037678-9 |x 1573-899X |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2023 |g number:4 |g month:05 |g pages:503-508 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11055-023-01448-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2023 |e 4 |c 05 |h 503-508 | ||